Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals. On the positive side, financial performance improved with increased revenue, gross margin, and net income. However, significant risks were highlighted, including regulatory hurdles and competitive pressures. The absence of strategic discussions and unclear management responses in the Q&A add to the uncertainty. Without additional insights into strategic initiatives or shareholder returns, the stock price is likely to remain stable, leading to a neutral rating.
Key Financial Performance
Revenue Revenue for Q1 2026 was $100 million, representing a 5% increase year-over-year. This growth was driven by higher demand for our flagship product in international markets.
Gross Margin Gross margin improved to 75% in Q1 2026, up from 72% in Q1 2025. The improvement was attributed to cost optimization initiatives and favorable product mix.
Operating Expenses Operating expenses were $60 million in Q1 2026, a 10% decrease compared to Q1 2025. This reduction was due to streamlined operations and reduced marketing expenditures.
Net Income Net income for Q1 2026 was $20 million, compared to $15 million in Q1 2025, reflecting a 33% increase. The increase was primarily due to higher revenue and lower operating expenses.
Cash Flow Cash flow from operations was $25 million in Q1 2026, up from $18 million in Q1 2025, marking a 39% increase. This was driven by improved profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces regulatory challenges that could impact its ability to bring new products to market or maintain existing product approvals.
Market Conditions: Unfavorable market conditions could adversely affect the company's sales and revenue growth.
Competitive Pressures: Intense competition in the pharmaceutical industry could impact the company's market share and pricing power.
Economic Uncertainties: Economic uncertainties, including changes in healthcare policies and economic downturns, could affect the company's financial performance.
Strategic Execution Risks: Challenges in executing strategic initiatives could hinder the company's growth and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aaron Berg
Ahn Leerink
Amarin Results
Berg CEO
Byunghyun Ahn
CEO President
CFO Ketchum
Chief Scientific
Choi Goldman
Conference Instructions
Development Chief
Director Peter
Division Byunghyun
Division Kyuwon
Division day
EDT Aaron
Executive VP
Fishman Senior
Kyuwon Choi
Leerink Partners
Mr Sir
Officer Fye
President Research
Research Development
Research Division
Results Conference
Senior VP
Sir today
VP CFO
VP President
completion statement
conference host
gentleman Amarin
host Mr
AMRN Transcript
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call presented mixed signals. On the positive side, financial performance improved with increased revenue, gross margin, and net income. However, significant risks were highlighted, including regulatory hurdles and competitive pressures. The absence of strategic discussions and unclear management responses in the Q&A add to the uncertainty. Without additional insights into strategic initiatives or shareholder returns, the stock price is likely to remain stable, leading to a neutral rating.
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. While there are positive signs such as strong financial health and restructuring efforts leading to reduced losses, the decline in revenue across all regions and potential risks in market dynamics and regulatory approvals offset these positives. The Q&A reveals some confidence in maintaining exclusivity but lacks clarity on key strategic moves, which could cause investor uncertainty. Given these factors, the overall sentiment is neutral, with no significant catalyst for a strong stock price movement.
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call highlights strong financial performance with a 17% revenue increase and significant cost reductions. The global restructuring is expected to save $70 million, and the company is on a path to positive cash flow. New partnerships, especially in Europe with Recordati, are promising for future revenue streams. Despite some concerns about declining margins and upfront restructuring costs, the overall outlook is optimistic with a leaner operating model and strong cash reserves. The Q&A session reinforced positive sentiment with management's focus on strategic partnerships and market expansion.
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript
Unknown7-30
The earnings call showed mixed signals: strong financial position and strategic partnerships, but challenges with U.S. market share and cash flow uncertainty. Revenue growth in Europe and global expansion are positives, but U.S. revenue decline and operational risks from restructuring are concerns. The Q&A revealed some uncertainty in long-term strategies, impacting sentiment. Overall, these factors balance out, leading to a neutral outlook.
AMRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
